Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...

CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

CHICAGO – An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, according to results presented at the American Association for ...

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and Adolescents Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in ...

Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study Thromboembolism is ...

Years of caring for children with solid tumors and looking into the eyes of parents starved for hope have led Catherine Bollard to what she calls the most important moment of her career. Children’s ...

Rhabdomyosarcoma, a common form of soft tissue sarcoma in pediatric patients with outcomes that have improved through research, is rare among older patients, who also have significantly poorer ...